Gallant Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Gallant Therapeutics's estimated annual revenue is currently $11.3M per year.
- Gallant Therapeutics's estimated revenue per employee is $155,000
- Gallant Therapeutics's total funding is $93M.
Employee Data
- Gallant Therapeutics has 73 Employees.
- Gallant Therapeutics grew their employee count by 20% last year.
Gallant Therapeutics's People
Name | Title | Email/Phone |
---|
Gallant Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Gallant Therapeutics?
Gallant Therapeutics is a clinical-stage animal health biotechnology company setting a new standard in animal health by harnessing the power of stem cell therapy to treat the root cause of diseases in dogs and cats. Our pipeline of off-the-shelf mesenchymal stem cell (MSC) therapies has the potential to treat a broad range of diseases, including canine and feline osteoarthritis (OA), feline chronic kidney disease (CKD), and others. The first product based on our uterine-derived platform for feline chronic gingivostomatitis (FCGS), is on track for conditional approval by the FDA in 2025. United by a love of and commitment to animals, Gallant’s team includes industry pioneers in veterinary regenerative medicine with deep experience in cell therapy product development, manufacturing and commercialization.
keywords:N/A$93M
Total Funding
73
Number of Employees
$11.3M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $23.2M | 73 | 22% | N/A |
#2 | $9.5M | 73 | -1% | N/A |
#3 | $14.4M | 73 | 33% | N/A |
#4 | $6.6M | 73 | -10% | N/A |
#5 | $9.9M | 73 | 4% | N/A |